In January 2023, the USDA’s Center for Veterinary Biologics granted a conditional license to Dalan Animal Health for the world’s first vaccine for any insect — a vaccine designed to protect honeybee colonies against American foulbrood, the most destructive bacterial brood disease in beekeeping. This wasn’t a symbolic first; it was a genuine regulatory and scientific milestone, and the story has kept moving since: as of late 2025 the company has completed a fresh round of efficacy trials toward full licensure, and separate 2024 data suggests the same technology might eventually protect against a viral threat too.
This site has already covered American vs. European foulbrood, the history of American foulbrood laws and apiary inspection, and antibiotic treatment options like Terramycin — this article is about the newest development in that century-plus-old fight, where the science actually came from, and what the published data since 2023 actually shows.
Key Takeaways
- American foulbrood, caused by the spore-forming bacterium Paenibacillus larvae, has historically had no real cure — the only options have been antibiotic suppression (which doesn’t eliminate spores) or destroying the affected colony and equipment.
- Dalan Animal Health’s vaccine contains killed whole-cell Paenibacillus larvae bacteria mixed into queen feed — the queen then transfers immune-priming material to developing larvae via royal jelly, a mechanism developed in partnership with University of Georgia researchers.
- It received a conditional USDA license in January 2023 — the first licensed vaccine for any insect species in history — meaning limited commercial distribution was authorized while further efficacy data was collected.
- A peer-reviewed 2022 field trial (Dickel et al., Frontiers in Veterinary Science) found the vaccine prevented 28-30% of larval deaths in an Austrian trial site and 50% in a Spanish trial site, with no signs of harm to vaccinated queens.
- As of November 2025, Dalan says it has completed the efficacy trials needed for full USDA licensure, with approval unlikely before the 2027 season; separate September 2024 data reported an 83% reduction in a deformed wing virus variant, though the company is explicit that this doesn’t yet amount to a formal efficacy claim.
Table of Contents
- The Problem American Foulbrood Actually Solves
- Where This Vaccine Actually Came From
- How the Vaccine Actually Works
- What “Conditional License” Actually Means
- What the Published Efficacy Data Actually Shows
- Beyond Foulbrood: Early Signs It Might Fight a Virus Too
- Where It Stands Now
- What This Means for Beekeepers Right Now
- Frequently Asked Questions
The Problem American Foulbrood Actually Solves
American foulbrood is widely considered the most consequential bacterial disease in managed honeybee colonies, caused by the spore-forming bacterium Paenibacillus larvae. Its spores are extraordinarily durable — they can remain viable in old equipment, comb, and honey for decades — which is exactly why the traditional response to a confirmed infection has so often been the destruction of the entire hive and its equipment by burning, rather than an attempt at treatment. Antibiotics like Terramycin (oxytetracycline) can suppress active infection but don’t eliminate the underlying spore contamination, meaning the disease can resurface once antibiotic pressure lifts. It’s a genuinely hard problem, and it’s been a hard problem for over a century of organized apiary inspection.
Every prior tool available to beekeepers has been reactive — detect the infection, then destroy or suppress it. A vaccine, if it works and eventually reaches full licensure, would be the first genuinely preventive option in that entire history.
Where This Vaccine Actually Came From
Dalan Animal Health is headquartered in Athens, Georgia, where it operates as a tenant of the University of Georgia’s Innovation District — a deliberate research partnership, not just a coincidence of location. According to the University of Georgia College of Agricultural & Environmental Sciences (CAES), Dalan was the first tenant to combine CAES researchers directly within that district, and the arrangement has also supported student internships into biotech careers. Keith Delaplane, a UGA professor of entomology and director of the UGA Bee Program, has been publicly enthusiastic about what a working vaccine could mean for an industry that has had no comparable preventive tool before.
The vaccine represents “a game-changer for beekeepers.” — Keith Delaplane, Professor of Entomology and Director of the UGA Bee Program, University of Georgia CAES
Dalan’s own CEO and co-founder, Dr. Annette Kleiser, framed the January 2023 announcement in similar terms, tying the vaccine to the broader mission behind the company rather than presenting it as just a single product launch.
“We are committed to providing innovative solutions to protect our pollinators and promote sustainable agriculture.” — Dr. Annette Kleiser, CEO and Co-Founder, Dalan Animal Health, January 4, 2023 announcement
How the Vaccine Actually Works
Dalan’s vaccine takes a different approach entirely from any prior American foulbrood control method: it contains killed, whole-cell Paenibacillus larvae bacteria, and is administered by being mixed into queen feed (“queen candy”). From there, the mechanism relies on the queen’s own biology — material from the vaccine is incorporated into the royal jelly and other secretions she produces, which is then fed to developing larvae, priming an immune response in the next generation of bees before they’re ever exposed to a real infection. This is conceptually closer to how some other animal vaccines confer passive, maternally-transferred protection than it is to a typical human vaccine given directly to the individual being protected, and it depends on the same bee immune-system pathways that let a colony mount any immune response at all — there’s no needle involved anywhere in the process.
In this interview, Mann Lake Bee Supply talks with a Dalan Animal Health representative about how the vaccine is administered in practice, what commercial beekeepers should expect when using it, and how it fits alongside existing American foulbrood management — a useful practical walkthrough of the mechanism described above.
| Approach | How it works | Limitation |
|---|---|---|
| Colony destruction (traditional) | Burn infected hive and equipment to eliminate spore contamination | Total economic loss of the colony and equipment; purely reactive |
| Antibiotic treatment (e.g., Terramycin) | Suppresses active bacterial infection in the colony | Doesn’t eliminate durable spores; infection can resurface |
| Dalan’s vaccine | Killed-bacteria material fed to the queen, transferred to larvae via royal jelly to prime immune response | Conditionally licensed pending full efficacy data; not yet a universally available, fully licensed product |
What “Conditional License” Actually Means
The USDA’s Center for Veterinary Biologics grants conditional licenses to allow a promising veterinary product limited market availability while the manufacturer continues collecting the efficacy data required for full licensure — it’s a genuine regulatory pathway, not an informal workaround, but it does mean the vaccine has not gone through the complete approval process a fully licensed product has. The USDA issued the license, dated January 4, 2023, for an initial two-year term. Since then the vaccine has been distributed on a limited basis to commercial beekeepers, manufactured by Diamond Animal Health of Des Moines, Iowa (a Heska Corp. subsidiary) on Dalan’s behalf.
What the Published Efficacy Data Actually Shows
Independent of the company’s own announcements, a peer-reviewed safety and efficacy study gives a clearer picture of how well the vaccine actually performed under field conditions. Dickel et al. published their findings in Frontiers in Veterinary Science in October 2022, testing the oral vaccination at two sites: Graz, Austria, and Marchamalo, Spain.
The results varied by site and challenge but were consistently protective: vaccination prevented 30% of larval deaths in the first Austrian challenge and 28% in the second (both statistically significant at p=0.02), and 50% of larval deaths at the Spanish site (p=0.01). Just as importantly for a product administered directly to queens, the study reported that all vaccinated queens survived the process and showed no signs of stress, and overall colony losses after placement didn’t differ significantly between vaccinated and control groups.
Sample sizes were modest — partly limited by ordinary queen failures unrelated to the vaccine itself, a real-world constraint of working with live colonies rather than a lab population — so this is early field evidence rather than a large-scale definitive trial. It’s still a meaningfully more specific and independently reviewed data point than most first-in-class veterinary products have publicly available this early in their regulatory life.
Beyond Foulbrood: Early Signs It Might Fight a Virus Too
In September 2024, Dalan reported a finding that goes beyond the vaccine’s original American foulbrood target entirely: an 83% reduction in levels of deformed wing virus variant B (DWV-B), one of the most damaging viral pathogens affecting honeybee colonies worldwide and a major contributor to colony losses linked to Varroa mite infestation. If it holds up, Dr. Kleiser has described it as potentially the first documented case of activating an invertebrate’s immune system with a dead bacterium to defend against an unrelated virus — a genuinely novel mechanism, not just a bigger version of the original AFB effect.
The company has been careful not to overstate this yet: Dalan states directly that the current data “do not constitute an efficacy claim for DWV-B,” meaning this is a promising early signal reported to industry press, not a claim the vaccine has been shown, tested, or licensed to protect against viral disease. Worth tracking, not worth relying on for colony management decisions today.
Where It Stands Now
As of November 2025, Dalan Animal Health announced it had successfully completed the summer 2025 efficacy trials required to support full USDA licensure and was submitting that data for review that same month.
“This past summer, we performed efficacy trials similar to those we conducted for our conditional license. The results were excellent.” — Dr. Annette Kleiser, CEO and Co-Founder, Dalan Animal Health, November 4, 2025 announcement
Trade press coverage of that announcement has suggested full licensure could realistically arrive as early as the 2027 season, which would move the vaccine from limited conditional distribution to a fully approved, more widely available product. Full licensure would also likely mean more independent, published efficacy data becomes available for beekeepers and researchers to evaluate directly, rather than relying primarily on the company’s own trial announcements.
What This Means for Beekeepers Right Now
For most beekeepers today, the honest, practical answer is: not much changes immediately. The vaccine remains conditionally licensed and distributed on a limited basis, primarily to commercial operations, rather than being a shelf-available product for hobbyists. The existing toolkit — good apiary hygiene, the inspection and reporting requirements most states still enforce, and antibiotic treatment where appropriate and legal — remains the operative reality for now. What’s genuinely worth tracking is the path toward full licensure, since a fully approved, more widely distributed vaccine would represent the first real preventive tool against a disease beekeeping has otherwise only ever been able to react to.
Frequently Asked Questions
Can I buy the American foulbrood vaccine for my own hives right now?
It remains conditionally licensed and has been distributed on a limited basis, primarily to commercial beekeeping operations, rather than being broadly available to hobbyist beekeepers — availability may change as the company pursues full licensure.
Does the vaccine replace the need to report a confirmed American foulbrood case?
No — state apiary inspection and reporting requirements for confirmed American foulbrood remain in effect regardless of vaccine use, since the vaccine is a preventive tool aimed at reducing new infections, not a substitute for existing disease-control regulations.
Is this really the first vaccine ever made for an insect?
Yes — coverage of the January 2023 USDA conditional license specifically describes it as the first licensed vaccine for any insect species, not just the first for honeybees, making it a genuine first in veterinary science broadly.
How is the vaccine actually given to a colony?
It’s mixed into queen feed; the queen incorporates vaccine material into royal jelly and other secretions fed to developing larvae, priming their immune response before exposure to a real infection — beekeepers aren’t vaccinating individual larvae or adult bees directly.
Does published research actually confirm it works, or is that just the company’s word?
Independent, peer-reviewed data exists: a 2022 field trial published in Frontiers in Veterinary Science found the vaccine reduced larval deaths by 28-50% depending on the trial site, with no evidence of harm to vaccinated queens — a genuinely independent data point beyond Dalan’s own announcements.
Will the same vaccine eventually protect against viruses like deformed wing virus?
Maybe, but it’s not established yet. Dalan reported an 83% reduction in a deformed wing virus variant in September 2024, but the company itself says that data doesn’t yet amount to a formal efficacy claim — it’s an early signal worth watching, not a current use of the product. Beyond this whole-cell vaccine approach, researchers are also exploring newer RNA-based treatments for bee diseases that target viruses like DWV more directly.
When will the vaccine be fully licensed instead of just conditionally licensed?
Dalan submitted efficacy data toward full USDA licensure in November 2025, and trade press coverage has suggested approval could arrive as early as the 2027 season at the earliest — full licensure is not yet guaranteed or scheduled.
Whether or not full licensure arrives on the timeline industry coverage currently expects, the vaccine already represents something beekeeping has never had before against American foulbrood: a genuine attempt at prevention, backed by independent peer-reviewed data, rather than just faster detection and destruction after the fact.
Image credits: Photo: Levi Asay, CC BY-SA 3.0, via Wikimedia Commons; Photo: Dalibor Titera, CC BY-SA 4.0, via Wikimedia Commons; Photo: Tanarus, CC BY-SA 3.0, via Wikimedia Commons.
